醋酸甲羟孕酮长效注射剂与子宫内膜癌和卵巢癌

Depot-medroxyprogesterone acetate (DMPA) and cancer of the endometrium and ovary.

作者信息

Lumbiganon P

机构信息

Department of Obstetrics and Gynecology, Faculty of Medicine, Khon Kaen University, Thailand.

出版信息

Contraception. 1994 Mar;49(3):203-9. doi: 10.1016/0010-7824(94)90038-8.

DOI:10.1016/0010-7824(94)90038-8

PMID:8200214

Abstract

This review addresses possible associations between depot-medroxy-progesterone acetate (DMPA) and endometrial and epithelial ovarian cancers. Two unexpected endometrial carcinomas were observed at autopsy of rhesus monkeys treated for 10 years with 50 times the human doses of DMPA. A record linkage in the USA did not suggest any association between DMPA and endometrial cancer. A multicentre case-control study in Thailand showed a strong protective effect of DMPA for endometrial cancer. Studies from the USA, Mexico and Thailand did not observe any association between use of DMPA and epithelial ovarian cancer. The available information, therefore, indicates that use of DMPA protects against endometrial cancer and is not associated with epithelial ovarian cancer.

摘要

本综述探讨了醋酸甲羟孕酮长效注射剂（DMPA）与子宫内膜癌和上皮性卵巢癌之间可能存在的关联。在接受了50倍人类剂量DMPA治疗10年的恒河猴尸检中，发现了两例意外的子宫内膜癌。美国的一项记录链接研究未表明DMPA与子宫内膜癌之间存在任何关联。泰国的一项多中心病例对照研究显示，DMPA对子宫内膜癌有很强的保护作用。美国、墨西哥和泰国的研究未观察到使用DMPA与上皮性卵巢癌之间存在任何关联。因此，现有信息表明，使用DMPA可预防子宫内膜癌，且与上皮性卵巢癌无关。